Redcare Pharmacy Reports Strong Q3 Growth, Reaffirms Full-Year Guidance
Redcare Pharmacy's robust third-quarter performance, featuring 25% sales growth and significant prescription medication expansion in Germany, demonstrates the company's successful execution of its European e-pharmacy strategy while maintaining profitability targets.
Redcare Pharmacy N.V. reported preliminary third-quarter sales figures showing sustained growth momentum across both prescription and non-prescription segments, prompting the company to reaffirm its full-year guidance. The European e-pharmacy leader recorded total sales of EUR 719 million in Q3 2025, representing a 25.2% increase compared to the same period last year.
The company's performance was particularly strong in the prescription medication segment, where German operations saw an 82.1% year-over-year increase to EUR 126 million. Total prescription sales across all markets grew 42.3% to EUR 272 million, while non-prescription sales increased 16.7% to EUR 448 million. Both the DACH and International reporting segments achieved over 25% organic sales growth during the quarter.
CEO Olaf Heinrich emphasized the company's continued profitable growth trajectory, stating that the strong Q3 performance has already lifted year-to-date EBITDA margin into the company's full-year guidance range of 2 to 2.5%. The company's customer base expanded to 13.7 million active customers, while customer satisfaction metrics showed significant improvement with the net promoter score rising to well over 70.
Looking ahead to the fourth quarter, Redcare Pharmacy expects accelerated prescription growth in Germany combined with the customary seasonal uplift in order volumes. The company remains confident in achieving at least EUR 500 million in prescription sales for the full year. Management confirmed that all elements of the full-year guidance remain unchanged, reflecting the company's stable financial steering throughout the current transition period.
The DACH segment, comprising Germany, Austria and Switzerland, recorded sales of EUR 587 million in Q3, with prescription medication sales growing 42.3% to EUR 272 million. The International segment, covering Belgium, Italy, France and the Netherlands, maintained its rapid growth pace with sales increasing 25.4% to EUR 132 million. Year-to-date figures show total sales of EUR 2.15 billion, representing a 27% increase compared to the same period in 2024.
Redcare Pharmacy will release its full interim report for the third quarter of 2025 on October 29, 2025. The company's continued strong performance in the competitive European e-pharmacy market underscores the growing consumer shift toward digital healthcare solutions and validates the company's strategic focus on both prescription and non-prescription segments. Additional information about the company's performance and strategy can be found at https://www.redcare-pharmacy.com.